Edition:
India

Ultragenyx Pharmaceutical Inc (RARE.OQ)

RARE.OQ on NASDAQ Stock Exchange Global Select Market

49.16USD
19 Jan 2018
Change (% chg)

$1.91 (+4.04%)
Prev Close
$47.25
Open
$47.07
Day's High
$49.36
Day's Low
$47.05
Volume
234,250
Avg. Vol
169,597
52-wk High
$91.17
52-wk Low
$43.14

Latest Key Developments (Source: Significant Developments)

Ultragenyx Announces Update To UX007 Development Program In Long-Chain Fatty Acid Oxidation Disorder Patients
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX ANNOUNCES UPDATE TO UX007 DEVELOPMENT PROGRAM IN LONG-CHAIN FATTY ACID OXIDATION DISORDER PATIENTS.ULTRAGENYX PHARMACEUTICAL INC - EXPECTS THAT DECISION ON A POTENTIAL FILING FOR APPROVAL BASED ON PHASE 2 DATA WILL BE MADE IN MID-2018.ULTRAGENYX PHARMACEUTICAL - SAFETY PROFILE WAS CONSISTENT WITH WHAT HAS BEEN PREVIOUSLY OBSERVED WITH UX007.  Full Article

Ultragenyx Sells Priority Review Voucher For $130 Mln
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX SELLS PRIORITY REVIEW VOUCHER FOR $130 MILLION.ENTERED INTO A DEFINITIVE AGREEMENT TO SELL ITS RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER TO NOVARTIS.  Full Article

Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA KIRIN ANNOUNCE BUROSUMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA IN CHILDREN.ULTRAGENYX PHARMA SAYS CHMP'S OPINION IS BEING REFERRED TO EC, FOR FINAL DECISION ON GRANT OF CONDITIONAL MARKETING AUTHORIZATION.ULTRAGENYX PHARMA SAYS DECISION ON GRANT OF CONDITIONAL MARKETING AUTHORIZATION IS EXPECTED IN Q1 2018.  Full Article

ULTRAGENYX SAYS FDA APPROVES MEPSEVII FOR GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX ANNOUNCES FDA APPROVAL OF MEPSEVII™ (VESTRONIDASE ALFA), THE FIRST THERAPY FOR PROGRESSIVE AND DEBILITATING RARE GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII.ULTRAGENYX PHARMACEUTICAL - OPINION FOR VESTRONIDASE ALFA FROM COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE IS EXPECTED IN H1 2018​.ULTRAGENYX PHARMACEUTICAL INC - ‍MEPSEVII WILL BE AVAILABLE TO PATIENTS IN U.S. LATER IN NOVEMBER​.  Full Article

FDA approves Ultragenyx Pharmaceutical's Mepsevii for rare genetic enzyme disorder‍​
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - FDA::Approved Ultragenyx Pharma's Mepsevii to treat pediatric, adult patients with inherited metabolic condition called mucopolysaccharidosis TYPE VII ‍​.  Full Article

Ultragenyx reports third quarter 2017 financial results
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Ultragenyx Pharmaceutical Inc :Ultragenyx Pharmaceutical Inc- ‍cash, cash equivalents, and investments were $396.0 million as of September 30, 2017​.Q3 loss per share $1.87.Q3 earnings per share view $-1.86 -- Thomson Reuters I/B/E/S.  Full Article

ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION.ULTRAGENYX PHARMACEUTICAL INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE FOR BLA IS APRIL 17, 2018​.ULTRAGENYX PHARMACEUTICAL INC - FDA HAS NOT INFORMED COMPANIES WHETHER AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION WILL BE NEEDED​.ULTRAGENYX - FDA ACCEPTED BLA FOR BUROSUMAB TO TREAT PEDIATRIC, ADULT PATIENTS WITH X-LINKED HYPOPHOSPHATEMIA, GRANTED PRIORITY REVIEW STATUS​.  Full Article

Ultragenyx files for resale of upto 374,590 shares of co
Thursday, 11 Aug 2016 

Ultragenyx Pharmaceutical :Files for resale of upto 374,590 shares of co by Takeda Pharma Co ltd/its pledgees, assignees/successor-in-interest.  Full Article

Ultragenyx Pharmaceutical reports Q2 loss $1.46/shr
Tuesday, 9 Aug 2016 

Ultragenyx Pharmaceutical Inc : Ultragenyx reports second quarter 2016 financial results and corporate update . Q2 shr loss $1.46 .Q2 shr view $-1.44 -- Thomson Reuters I/B/E/S.  Full Article

Ultragenyx Pharmaceutical files for stock shelf of upto $150 mln
Saturday, 2 Jul 2016 

Ultragenyx Pharmaceutical Inc :Files for stock shelf of upto $150 million - SEC filing.  Full Article

BRIEF-Capital International Investors Reports 10.3 Pct Passive Stake In Ultragenyx

* CAPITAL INTERNATIONAL INVESTORS REPORTS 10.3 PERCENT PASSIVE STAKE IN ULTRAGENYX PHARMACEUTICAL INC AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text for Eikon: (http://bit.ly/2D1HymY) Further company coverage: